论文部分内容阅读
目的 :探讨血清P53Ab作为肿瘤标记物的可能性以及与肿瘤预后的关系。方法 :用酶联免疫分析法 (ELISA)检测正常人 1 5例、乳腺良性肿瘤 1 7例、乳癌 58例血清的P53Ab。结果 :乳癌血清P53Ab阳性率 2 9.31 % ,正常人和乳腺良性肿瘤患者血清P53Ab阴性。P53Ab与肿瘤大小有关 ,与腋淋巴结转移和激素受体情况无关。结论 :血清P53Ab可预示患癌或癌瘤复发的危险性 ,但与癌瘤预后关系不大。
Objective: To explore the possibility of serum P53Ab as a tumor marker and its relationship with tumor prognosis. Methods: Serum P53Ab was detected by enzyme-linked immunosorbent assay (ELISA) in 15 normal individuals, 17 benign breast tumors and 58 breast cancer patients. Results: The positive rate of P53Ab in breast cancer was 2 9.31%. The serum P53Ab in normal and breast benign tumor was negative. P53Ab is associated with tumor size and has nothing to do with axillary lymph node metastasis and hormone receptor status. Conclusion: Serum P53Ab can predict the risk of cancer or cancer recurrence, but not with the prognosis of cancer.